Oncology Business Management

Internationally renowned medical oncologist Thomas J. Lynch Jr, MD, has been named the new president and director of the Fred Hutchinson Cancer Research Center.

After witnessing 10 years of breakthroughs across the spectrum of cancer care, oncology experts are looking ahead as a new decade begins to capitalize on those wide-ranging therapeutic and diagnostic gains.

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.

The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.

A pair of fellows will be able to advance their innovative technology-based projects thanks to the OncLive® Innovation Challenge: Innovative Technology in Cancer Care.

Karnofsky Performance Status and ECOG performance status alone leaves a lot to be desired for the practicing oncologist.

Despite the strides made by women over the past 170 years, significant disparities remain, especially in academic medicine.

Focusing on the needs of patients with cancer who were likely to be “superutilizers” of healthcare resources resulted in lower costs, fewer hospital admissions, and higher patient satisfaction scores for Crystal Run Healthcare.

After 3 years of struggling to meet targets for improved care quality and cost efficiency, many of the 175 practices that have remained in the Oncology Care Model of the Centers for Medicare & Medicaid Services have a decision to make: Assume a share of the downside risk for failure to meet financial targets or exit the OCM by December 3.

When discussing the topic of vaccination to prevent serious childhood illness, an increasing number of individuals refuse to accept the unequivocally demonstrated value of this public health strategy despite the very low risk of harm.

A large proportion of medical waste in oncology is considered hazardous and must be disposed of correctly.

Although use of wearable mobile health monitors has soared in other fields of healthcare, adoption of these electronic devices has lagged in oncology.

The often intense and frequently highly focused effort to seek scientific purity in answering questions within cancer clinical trials raises serious concerns regarding the ethical foundation of certain studies.

The ACCC David King Community Clinical Scientist Award was awarded to Paul D. Hansen, MD, FACS, a pioneering leader in research on minimally invasive approaches to major liver and pancreas surgery and the promise these techniques hold for improving the quality of care, the patient experience, and potentially reducing healthcare costs.

With just 2 more years to go in the Oncology Care Model, CMS is proposing a next-generation payment system that would include more private payers and hold practices more accountable for quality and costs of care.

President Donald Trump is nominating Stephen M. Hahn, MD, FASTRO, as the next commissioner of the FDA.

In July 2019, Centers for Medicare & Medicaid proposed the Radiation Oncology Model, an important step forward in allowing the nation’s 4500 radiation oncologists to join in the transition to value-based healthcare.

Studies have raised doubts about the value Medicare and other payers are getting for the care they pay for, including in oncology. This has intensified the demand for new value-based care models such as the Merit-based Incentive Payment System and the Oncology Care Model.

Certain themes and questions about individualized, scientifically unanswerable dilemmas often recur when talking with patients and families about treatment.